RecruitingPHASE1, PHASE2NCT05589896
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Studying Acute biphenotypic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ossium Health, Inc.
- Intervention
- Ossium HPC Marrow, Bone Marrow Transplant(other)
- Enrollment
- 12 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2027
Study locations (9)
- City of Hope, Duarte, California, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
- Henry Ford Cancer Institute, Detroit, Michigan, United States
- Oregon Health and Science University, Portland, Oregon, United States
- TriStar Bone Marrow Transplant, Nashville, Tennessee, United States
- St. David's South Austin Medical Center, Austin, Texas, United States
- Methodist Hospital, Texas Transplant, San Antonio, Texas, United States
- University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05589896 on ClinicalTrials.govOther trials for Acute biphenotypic leukemia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07517510HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).Guangdong Second Provincial General Hospital
- RECRUITINGPHASE1, PHASE2NCT07356154A Study of Revumenib and Mezigdomide in People With LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT07537738Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid LeukemiaPeking University People's Hospital
- RECRUITINGNANCT05794880MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingMedical College of Wisconsin
- ACTIVE NOT RECRUITINGPHASE2NCT03399773Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic SyndromesFred Hutchinson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04797767Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsUniversity of Washington
- ACTIVE NOT RECRUITINGPHASE2NCT04975919Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT04128501Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingM.D. Anderson Cancer Center